No biomarker	Endometrial Adenocarcinoma	No biomarker	Endometrial Adenocarcinoma	ZN-c3 Sensitive: B - Late Trials ZN-c3 Sensitive : B	ZN-c3 Sensitive: B - Late Trials ZN-c3 Sensitive : B
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MYCN amplification	Small Cell Lung Cancer	MYCN amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CDKN2A mutation + TP53 mutation	Small Cell Lung Cancer	CDKN2A mutation + TP53 mutation	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
TP53 mutation	Ovarian Cancer	TP53 mutation	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
TP53 mutation	Squamous Cell Carcinoma of Head and Neck	TP53 mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MYCL amplification	Small Cell Lung Cancer	MYCL amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
TP53 mutation	Triple Negative Breast Cancer	TP53 mutation	Triple Negative Breast Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2

WEE1 inhibitor

WEE1 inhibitor

Associations(66)

Associations
(66)